BioStock: Cereno Scientific nominates two new preclinical drug candidates

Swedish biotech Cereno Scientific continues to advance on its journey toward delivering innovative treatments for patients suffering from the deadliest disease worldwide: cardiovascular disease. While lead candidate CS1 is progressing in clinical phase II within the rare disease pulmonary arterial hypertension, the company has now nominated CS585 and CS014 as the next two candidates to develop and bring into the clinic.

Read the article at biostock.se:

https://www.biostock.se/en/2022/05/cereno-scientific-nominates-two-new-preclinical-drug-candidates/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/